Why Novo Nordisk Stock Popped Today

Novo Nordisk (NYSE: NVO) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was still up by about 1.2%.The stock is benefiting from an exclusive Reuters report published before the opening of trading that said the World Health Organization "plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time." Specifically, the organization will endorse the use of GLP-1 receptor agonists. This first-ever WHO endorsement of weight-loss treatments promises to boost Novo's attractiveness by increasing demand for semaglutide -- the GLP-1 receptor agonist the company markets as Zepbound for weight loss and Ozempic for diabetes. As Reuters points out, more than 1 billion people around the world suffer from obesity and are potential consumers of Novo Nordisk's drugs (as well as those marketed by rival Eli Lily). That's a total market 10x as big as the 100 million estimated U.S. adults who are obese. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool